ATE219791T1 - Antikörper gegen den urokinaserezeptor und ihre verwendung - Google Patents

Antikörper gegen den urokinaserezeptor und ihre verwendung

Info

Publication number
ATE219791T1
ATE219791T1 AT91918632T AT91918632T ATE219791T1 AT E219791 T1 ATE219791 T1 AT E219791T1 AT 91918632 T AT91918632 T AT 91918632T AT 91918632 T AT91918632 T AT 91918632T AT E219791 T1 ATE219791 T1 AT E219791T1
Authority
AT
Austria
Prior art keywords
par
mammal
antibodies
inhibiting
preventing
Prior art date
Application number
AT91918632T
Other languages
English (en)
Inventor
Keld Dan
Ebbe Ronne
Niels Behrendt
Vincent Ellis
Gunilla Hoyer-Hansen
Charles Pyke
Nils Bruenner
Original Assignee
Cancerforskningsfonden Af 1989
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancerforskningsfonden Af 1989 filed Critical Cancerforskningsfonden Af 1989
Application granted granted Critical
Publication of ATE219791T1 publication Critical patent/ATE219791T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/972—Plasminogen activators
    • G01N2333/9723—Urokinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
AT91918632T 1990-10-18 1991-10-18 Antikörper gegen den urokinaserezeptor und ihre verwendung ATE219791T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPCTDK9000270 1990-10-18
PCT/DK1991/000319 WO1992007083A1 (en) 1990-10-18 1991-10-18 Antibodies against the urokinase receptor and their use

Publications (1)

Publication Number Publication Date
ATE219791T1 true ATE219791T1 (de) 2002-07-15

Family

ID=8153643

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91918632T ATE219791T1 (de) 1990-10-18 1991-10-18 Antikörper gegen den urokinaserezeptor und ihre verwendung

Country Status (8)

Country Link
EP (2) EP1281404A3 (de)
JP (1) JPH07500486A (de)
AT (1) ATE219791T1 (de)
AU (1) AU661978B2 (de)
CA (1) CA2094276C (de)
DE (1) DE69133049T2 (de)
ES (1) ES2179036T3 (de)
WO (1) WO1992007083A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248715B1 (en) 1993-06-01 2001-06-19 Chiron Corporation Method of treating a urokinase-type plasminogen activator-mediated disorder
WO1994028145A2 (en) * 1993-06-01 1994-12-08 Chiron Corporation Expression of urokinase plasminogen activator inhibitors
JP2852192B2 (ja) * 1994-07-08 1999-01-27 カンセアフォースクニングスフォンデン・アフ・1989(フォンデン・チル・フレメ・アフ・エクスペリメンテル・カンセアフォースクニング) uPARのドメイン2+3のuPA結合部位および抗体
US6077508A (en) * 1998-03-23 2000-06-20 American Diagnostica Inc. Urokinase plasminogen activator receptor as a target for diagnosis of metastases
JP2002541482A (ja) * 1999-04-13 2002-12-03 ヴィレックス アクチェンゲゼルシャフト 診断及び治療のためのウロキナーゼレセプターに対する抗体の使用
AU2002358921A1 (en) * 2001-07-10 2003-04-28 Omnio Ab Novel drug targets for arthritis
WO2003014394A1 (fr) * 2001-08-03 2003-02-20 Asahi Medical Co., Ltd. Methode d'evaluation de la biocompatibilite
JP2004137151A (ja) * 2002-10-15 2004-05-13 Keio Gijuku 脳腫瘍の治療・診断薬
TW200813091A (en) * 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
EP2071313A4 (de) * 2006-09-28 2012-10-31 Shimadzu Corp Verfahren zur entparaffinisierung von in paraffin eingebetteten präparaten und verfahren zur analyse von in paraffin eingebetteten präparaten
JP2010512324A (ja) 2006-12-08 2010-04-22 アッテヌオン エル エル シー ウロキナーゼ型プラスミノーゲン活性化因子受容体エピトープ、それに由来するモノクローナル抗体及びそれらの使用方法
WO2010118979A1 (en) * 2009-04-07 2010-10-21 Velin-Pharma A/S Method and device for treatment of conditions associated with inflammation or undesirable activation of the immune system
US10539487B2 (en) 2010-03-04 2020-01-21 Ventana Medical Systems, Inc. Systems and methods for monitoring tissue sample processing
US10126216B2 (en) 2011-02-17 2018-11-13 Ventana Medical Systems, Inc. Method for tissue sample fixation
US10267769B2 (en) 2010-03-04 2019-04-23 Ventana Medical Systems, Inc. Processing system for processing specimens using acoustic energy
MA41842A (fr) * 2015-03-31 2018-02-06 Oblique Therapeutics Ab Nouveaux procédés de sélection d'épitope
GB201617002D0 (en) 2016-10-06 2016-11-23 Oblique Therapeutics Ab Multi-protease method

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923807A (en) * 1984-05-18 1990-05-08 New England Medical Center Hospitals Inc. Arg-Serpin human plasminogen activator inhibitor designated PAI-2
DE3902021A1 (de) * 1989-01-20 1990-07-26 Entec Verwendung von antipeptidergen mitteln, gegebenenfalls in kombination mit anti-androgenen mitteln zur behandlung des humanen prostatakarzinoms
EP1013285A3 (de) * 1989-04-07 2004-05-19 Cancerforskningsfonden af 1989 (fonden til fremme af eksperimentel cancerforskning) Plasminogen-Aktivator-Rezeptor vom Urokinasetyp

Also Published As

Publication number Publication date
DE69133049T2 (de) 2003-01-02
CA2094276C (en) 2005-08-23
WO1992007083A1 (en) 1992-04-30
AU8757291A (en) 1992-05-20
DE69133049D1 (de) 2002-08-01
EP1281404A3 (de) 2004-04-07
EP1281404A2 (de) 2003-02-05
EP0574391B1 (de) 2002-06-26
JPH07500486A (ja) 1995-01-19
CA2094276A1 (en) 1992-04-19
ES2179036T3 (es) 2003-01-16
EP0574391A1 (de) 1993-12-22
AU661978B2 (en) 1995-08-17

Similar Documents

Publication Publication Date Title
DE69133049D1 (de) Antikörper gegen den urokinaserezeptor und ihre verwendung
NO922238D0 (no) Aktiverbare, fibrinolytiske og antitrombotiske proteiner
ATE197067T1 (de) Plasminogen-aktivator-rezeptor vom urokinasetyp
DK0573545T3 (da) Monoklonale antistoffer mod receptor-inducerede bindingssteder
DK0724456T3 (da) CD40-Antistoffer
ATE72726T1 (de) Verwendung eins pflanzensubstrates.
NO922457D0 (no) Antistoffantagonister av humant interleukin-4
ATE421976T1 (de) Fab fragmentbibliotheken und verfahren für deren verwendung
FI903464A0 (fi) Foerfarande foer oxiderande denaturering av proteinanalyter.
DE69432645D1 (de) Monoklonale antikörper gegen isozyme der thymidinkinase
DE69124705D1 (de) Hexapeptide als liganden des anaphylatoxin-rezeptors
NO172596C (no) Apolipoprotein b-spesifikke monoklonale antistoffer produsert av to nye hybridomer, anvendelse av disse og diagnostiske systemer inneholdende disse
GB1533205A (en) Plasmin fractions and complexes thereof
DE68921136D1 (de) Transistorverstärker für hohe Anstiegsgeschwindigkeiten und kapazitive Belastungen.
Mattila Resources leveling of linear schedules: A mathematical approach using integer linear programming
DE68909515D1 (de) Durch antikoerper und liganden bewirkte zielrichtung von differentiationsinduktoren auf tumorzellen.
EP0672685A3 (de) Monoclonal Antikörper.
DE68917797D1 (de) Gegen menschliches Fibrinopepid A spezifische monoklonale Antikörper.
FR2415565A1 (fr) Perfectionnement a un wagon
ATE188248T1 (de) Monoklonale antikörper gegen rezeptor-induzierte bindungsstellen auf liganden, die an proteine der cytoadhesin-superfamilie binden
ATE56617T1 (de) Anti-urokinase monoklonaler antikoerper, seine herstellung und verwendung.
DE3877015D1 (de) Antikoerper enthaltende stabilisierte waesserige zusammensetzung.
Thirapakpoomanunt et al. An ELISA for optimization of horse antivenom digestion by pepsin
DE3888031D1 (de) Homocyclostatin und Cyclostatin enthaltende Polypeptide als Antihypertensiva.
DE69133082D1 (de) Gegen aus Thrombin und Thrombininhibitoren gebildete Komplexe gerichtete monoklonale Antikörper